NCT00543595View on ClinicalTrials.gov

MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Diabetes Mellitus, Type 2Metabolic Syndrome
Interventions
DRUG

MK0916

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00543595 - MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005) | Biotech Hunter | Biotech Hunter